Theratechnologies faces critical disruption in EGRIFTA SV supply following FDA-induced factory shutdown
Theratechnologies Inc., a leading biopharmaceutical company based in Montreal, has announced a potentially significant disruption in the supply of its body fat reduction medication, EGRIFTA SV, expected in early 2025. The looming shortage follows a voluntary shutdown of the company’s contract manufacturer’s facility in response to an inspection by the U.S. Food and Drug Administration […]
